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Abstract
Objective—To describe latency for patients with preterm premature membrane rupture 
(PPROM) between 24 0/7 and 31 6/7 weeks’ gestation.
Study Design—Secondary analysis of data collected prospectively in a multicenter clinical trial 
of magnesium sulfate for cerebral palsy prevention. Women with PPROM and fewer than 6 
contractions per hour at enrollment who were candidates for expectant management (n=1377) 
were included in this analysis. Length of latency was calculated in days by subtracting the time of 
delivery from the time of membrane rupture.
Results—At each week of gestation, median latency between 24-28 weeks was similar at 
approximately 9 days, but was significantly shorter with PPROM at 29, 30, and 31 weeks 
(p<0.001). In addition, the percentage of patients remaining undelivered at 7 days and 14 days was 
similar for PPROM between 24-28 weeks, but decreased significantly after that. For each 
gestational age, the proportion of patients remaining pregnant declined in a fashion similar to 
exponential pattern.
Conclusion—Median latency after PPROM is similar from 24-28 weeks’ gestation, but shortens 
with PPROM at and after 29 weeks.
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INTRODUCTION
Preterm premature rupture of membranes (PPROM) complicates 3% of pregnancies and is a 
significant contributor to perinatal morbidity and mortality. This increase in morbidity and 
mortality is primarily related to the gestational age at which PPROM and subsequent 
preterm delivery occurs. Management before 34 weeks’ gestation usually involves antibiotic 
administration and expectant management in an effort to prolong pregnancy. Length of 
latency until delivery appears to be inversely related to the gestational age at which PPROM 
occurs, but little data exist to describe this relationship against the background of 
prophylactic antibiotics.1,2 Our research network conducted a trial evaluating the use of 
magnesium sulfate to prevent cerebral palsy in patients at high risk of early preterm 
delivery.3 Because the majority of women entered into this large randomized trial had 
PPROM and were managed expectantly, it afforded the opportunity to estimate gestational 
age specific measures of latency in patients experiencing PPROM between 24-31 weeks’ 
gestation and who routinely received antibiotics for pregnancy prolongation.
MATERIALS AND METHODS
We conducted a secondary analysis of a clinical trial of magnesium sulfate for the 
prevention of cerebral palsy performed at the 20 centers of the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development Maternal Fetal Medicine Units 
Network.3 Participants were women with singleton or twin gestations at 24 0/7-31 6/7 
weeks’ gestation and were at high risk for spontaneous preterm delivery because of rupture 
of the membranes, advanced preterm labor, or an indicated preterm delivery. They were 
randomly allocated to treatment with magnesium sulfate as a 6-g bolus followed by a 
constant infusion of 2 g per hour, or matching placebo. The primary study was approved by 
the Institutional Review Board at all participating centers, and all patients gave informed 
consent.
Within this cohort, 1377 patients who experienced PPROM from 24 to 31weeks and were 
contracting fewer than 6 times per hour at the time of randomization are the subject of this 
analysis. Criteria for assignment of gestational age were standardized,4 as were criteria for 
the diagnosis of ruptured membranes. Neither the antibiotic treatment nor criteria for 
delivery were standardized, but antibiotics were routinely administered, and expectant 
management was routinely pursued until at least 32 weeks’ gestation or until the patient 
entered spontaneous labor, developed intrauterine infection or bleeding, or the fetal status 
was deemed non-reassuring. Study medication was stopped after 12 hours if the patient was 
undelivered and regular uterine contractions were not present. Certified research personnel 
collected information on the mother's demographic features, medical history, social history 
at enrollment, and maternal and neonatal outcome data at delivery. Information on residual 
amniotic fluid volume and cervical length were not collected.
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Latency was measured from time of reported rupture of membranes until time of delivery in 
hours. Median latency was calculated for patients with rupture at each week of gestational 
age between 24 to 31 weeks, rounded down to the nearest whole week (e.g. 28 0/7 to 28 6/7 
weeks grouped as 28 weeks). For each week of gestational age at time of PPROM, the 
percent of women remaining undelivered at 7 days and 14 days after PPROM was also 
calculated. Data were analyzed using SAS (SAS Institute, Cary, NC). Wilcoxon rank sum 
test was used to compare the median difference and Cochran-Armitage trend test was used 
to evaluate the trend of proportion changes. Multivariable regression analysis (proportional 
hazards regression or logistic regression) was performed to determine clinical factors 
contributing to duration of latency. We used the proportional hazard regression to analyze 
the latency as the outcome. Then, we used the logistic regression to analyze a binary 
indicator (whether the latency is greater than 7×24 hours) as the outcome. We also used the 
logistic regression to analyze another similar binary indicator (whether the latency is greater 
than 14×24 hours) as the outcome. Twin gestation, nulliparity and treatment group were 
considered for adjustment in the regression analysis.
RESULTS
Baseline maternal characteristics of the expectantly managed patients with PPROM are 
presented in Table 1. 97% of patients were treated with antibiotics, and <7% of patients 
delivered within 12 hours of randomization. Reasons for delivery included spontaneous 
labor (68%), infection (9%), non-reassuring fetal status (10%), and bleeding (2%). 
Information regarding the interval from time of PPROM to delivery is reported in Table 2, 
and illustrated in Figure 1. At each week of gestation, median latency between 24-28 weeks 
was similar at approximately 9 days, but was significantly shorter with PPROM at 29, 30, 
and 31 weeks (p<0.001, Wilcoxon rank sum test). In addition, the percentage of patients 
remaining undelivered at 7 days and 14 days was similar for PPROM between 24-28 weeks’ 
gestation, but decreased significantly after that (p<0.001 for both, Cochran-Armitage trend 
test). For all gestational ages evaluated, the proportion of patients remaining pregnant 
declined in an exponential pattern (data not shown). Multivariable analysis demonstrated 
that twin gestation (hazard ratio 1.58, 95% CI 1.29-1.94), but neither nulliparity nor 
treatment with magnesium sulfate was associated with shorter latency. For twin gestations, 
median latency for those with PPROM between 24-28 weeks (n=71) was 7.0 days 
(interquartile range 2.0, 13.0) and for twin gestations with PPROM 29-31 weeks (n=33) 
median latency was 2.0 days (1.0, 6.0). Median latency for the magnesium sulfate group was 
7.0 days, compared with 8.0 days for patients in the placebo arm (p = 0.13).
COMMENT
Preterm premature rupture of membranes is a common pregnancy complication, and is the 
precipitating cause of a significant portion of all preterm deliveries. Previous studies have 
noted that latency with PPROM can last for weeks, and that PPROM at earlier gestations 
appear to have longer latency to delivery.1,2 However, little data exist to describe latency at 
specific gestational ages. We have taken the opportunity to utilize a large and well described 
cohort of patients with PPROM to describe latency of PPROM occurring between 24 and 31 
weeks’ gestation. We found that time from membrane rupture to delivery remains relatively 
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constant from 24 -28 weeks’ gestation at 8-10 days, and then decreases to 5 days at 31 
weeks. Further, the finding of exponential decay at each gestational age allows for 
prediction of likelihood of latency persisting to any point in the future. As an example, 
PPROM at 29 weeks’ gestational age has a median latency of about 8 days, and roughly 
25% of patients will remain undelivered at about 16 days, and 12.5% at about 24 days.
When considering duration of latency in this cohort, we examined the effect of treatment 
with magnesium sulfate. No significant difference was seen between the treatment and 
control groups with regard to length of latency. Whether this absence of difference is due to 
insufficient dosing or lack of benefit of magnesium sulfate for this purpose cannot be 
determined.5 Another interesting finding was the considerably shorter median latency in 
twin gestations. The number of patients with twin gestations is too small to generate week 
specific ranges for latency, but counseling of patients in this situation should be different 
than for those patients with singleton pregnancy and PPROM.
Currently, the most common approach to management of PPROM at <34 weeks’ gestation is 
expectant management with antibiotics to prolong latency. This practice is based on the 
understanding that gestational age at delivery is the most important factor impacting 
neonatal outcome. However, some concerns have been raised recently regarding this 
approach, primarily because of the increasing risks of developing intrauterine infection with 
delaying delivery in the face of ruptured membranes and the concerns for neurologic injury 
associated with the fetal inflammatory response.6 We observed that less than half of patients 
with PPROM after 29 weeks’ gestation remained undelivered for more than a week, 
exposing the majority to risks of infection with uncertain benefit of pregnancy prolongation 
after completion of antenatal corticosteroids. Two recent studies have addressed this issue 
with mixed results regarding increasing neonatal complications being associated with longer 
latency.7,8 Manuck et al. found that in patients with PPROM, infection but not latency was 
associated with major perinatal morbidity, while Melamed et al. found higher rates of 
composite neonatal morbidity with latency greater than 7 days. Future studies regarding 
pregnancy prolongation could be helpful in determining the most beneficial management 
approach. Ultimately, it may be found that the risk benefit ratio for expectant management is 
not constant between 24-34 weeks’ gestation, and different clinical approaches may be more 
appropriate.
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Median latency in days (with interquartile range) by gestational age at PPROM.
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Table 1
Maternal baseline characteristics
Mean weeks gestation at randomization (SD) 28.3 (2.30)
Mean maternal age—years (SD) 26.5 (6.30)




Maternal race or ethnic group—no. (%)
    Black 610 (44.3)
    White 522 (37.9)
    Hispanic 209 (15.2)
    Other 36 (2.6)
Nulliparous—no. (%) 459 (33.3)
Twins—no. (%) 104 (7.6)
Smoking during pregnancy—no. (%) 398 (28.9)
*
In kg/m2
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Table 2
Interval in days (d) from time of PPROM to delivery
Gestational Age 24 N=171 25 N=166 26 N=138 27 N=169 28 N=172 29 N=185 30 N=181 31 N=195
Median latency 
(d) [Q1, Q3]




1 (ref) 1.0 [0.8,1.3] 1.0 [0.8,1.3] 1.1 [0.9,1.4] 1.2 [0.9,1.4] 1.5 [1.2,1.8] 1.7 [1.4,2.1] 1.9 [1.5,2.3]
Undelivered 7d 64% 61% 64% 60% 62% 53% 44% 42%
OR [95% CI] 1 (ref) 0.9 [0.6,1.3] 1.0 [0.6,1.6] 0.9 [0.6,1.3] 0.9 [0.6,1.4] 0.6 [0.4,0.9] 0.4 [0.3,0.7] 0.4 [0.3,0.6]
Undelivered 14d 34% 36% 41% 35% 34% 30% 21% 22%
OR [95% CI] 1 (ref) 1.1 [0.7,1.7] 1.3 [0.8,2.1] 1.0 [0.7,1.6] 1.0 [0.6,1.5] 0.8 [0.5,1.3] 0.5 [0.3,0.8] 0.5 [0.3,0.8]
*
risk of latency being less than for those with PPROM at 24 weeks
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